---
document_datetime: 2025-05-16 14:19:32
document_pages: 3
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/fingolimod-accord-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: fingolimod-accord-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 1.5316915
conversion_datetime: 2025-12-29 22:20:49.120014
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Fingolimod Accord

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, please also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive) .

| Application number   | Scope                                     | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|-------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| Variation type IB /  | C.I.2 Change(s) in the Summary of Product | 14/03/2025                          | 05/05/2025                                  | SmPC, Annex                      |           |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| EMA/VR/0000254070                     | Characteristics, Labelling or Package Leaflet of a generic/hybrid/biosimilar medicinal products following assessment of the same change for the reference product - C.I.2.a Implementation of change(s) for which no new additional data is required to be submitted by the MAH - Accepted C.I.2.a (IB) - To update section 4.3 of the SmPC in order to add suspected or confirmed progressive multifocal leukoencephalopathy (PML) as a new contraindication; update of section 4.4 of the SmPC to amend an existing warning on PML and to add a new warning on immune reconstitution inflammatory syndrome (IRIS) and update of section 4.8 of the SmPC in order to add IRIS as ADR with frequency not know. Furthermore, the educational materials are updated on information about IRIS and also updated to improve the general readability and better address key messages and recommendations for healthcare professionals and patients. The Package Leaflet and Annex II are updated accordingly. These updates follow the   |            |            | II and PL   |
|---------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|
| Variation type IA / EMA/VR/0000226764 | A. ADMINISTRATIVE CHANGES - A.6 Change in ATC Code / ATC Vet Code - Accepted                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 09/09/2024 | 04/04/2025 | SmPC        |

<div style=\"page-break-after: always\"></div>

| Article 61(3) / EMA/N/0000221326   | - Notification acc. Article 61(3) - Accepted Update of the package leaflet to include the list of local representatives.   | 10/07/2024   | 04/04/2025   | PL   |
|------------------------------------|----------------------------------------------------------------------------------------------------------------------------|--------------|--------------|------|